SCHEMBL16432224

SCHEMBL16432224

c1ccc(Oc2ccc(-c3ncnc4cc[nH]c34)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 3/20 0.46
EGFR P00533 2/20 0.46
ERBB3 P21860 2/20 0.46
ERBB4 Q15303 2/20 0.46
TTBK1 Q5TCY1 1/20 0.43
TTBK2 Q6IQ55 1/20 0.43
DYRK1A Q13627 1/20 0.42
TNK2 Q07912 3/20 0.42
TRPA1 O75762 1/20 0.42
JAK2 O60674 1/20 0.42
LTA4H P09960 3/20 0.41
NUDT14 O95848 2/20 0.40
NUDT5 Q9UKK9 2/20 0.40
KDR P35968 1/20 0.40
TEK Q02763 1/20 0.40
BTK Q06187 2/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16432196 0.82 TRPA1 (0.55) ERBB2EGFRERBB3ERBB4TTBK1
SCHEMBL16432121 0.76 EGFR (0.71) ERBB2EGFRERBB3ERBB4TTBK1
SCHEMBL15347068 0.75 ADORA2A (0.71) ERBB2NUDT14NUDT5KDRTEK
SCHEMBL6435658 0.69 ERBB2 (0.47) ERBB2EGFRERBB3ERBB4DYRK1A
SCHEMBL17423539 0.69 ATM (0.46) ERBB2TTBK1TTBK2DYRK1ALTA4H
SCHEMBL18741409 0.66 PDE3B (0.43) ERBB2TNK2LTA4HBTKNPC1
SCHEMBL6736901 0.65 NPC1 (0.68) LTA4HNUDT14NUDT5PIK3CDPIK3CA
SCHEMBL5151126 0.65 NISCH (0.69) LTA4HNPC1SCN4ARAB9A
SCHEMBL7089361 0.65 GSTP1 (0.46) TNK2LTA4HBTKNPC1SCN4A
SCHEMBL6406035 0.64 LTA4H (0.75) LTA4HNPC1SCN4ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105814057-B Pyrimidines, pyridines and pyrazines as BTK inhibitors and uses thereof 默克专利有限公司 2019-05-03 CN disclosed
EP-3049417-B1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2018-10-17 EP disclosed
US-10005784-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2018-06-26 US disclosed
US-10005784-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2018-06-26 US disclosed
US-9738648-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2017-08-22 US disclosed
US-9738648-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2017-08-22 US disclosed
US-20170226113-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-08-10 US disclosed
US-20170226113-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-08-10 US disclosed
EP-3049417-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2016-08-03 EP disclosed
CN-105814057-A Pyrimidines, pyridines and pyrazines as BTK inhibitors and uses thereof 默克专利有限公司 2016-07-27 CN disclosed
US-20160159804-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-06-09 US disclosed
US-20160159804-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-06-09 US disclosed
WO-2015017502-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2015-02-05 WO disclosed
WO-2015017502-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2015-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226113-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN ERBB2 139/4885EGFR 1018/4885ERBB3 319/4885
US-20160159804-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN ERBB2 139/4885EGFR 1018/4885ERBB3 319/4885
US-10005784-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof BTK, SYK, LYN ERBB2 143/4885EGFR 1046/4885ERBB3 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.